Herpesvirus envelope glycoprotein gp350, N-terminal B domain
This entry consists of the envelope glycoprotein gp350 from Epstein-Barr virus (also known as BLLF1 viral late glycoprotein). It is the most abundantly expressed glycoprotein in the viral envelope of Herpesviruses and is the major antigen responsible ...
This entry consists of the envelope glycoprotein gp350 from Epstein-Barr virus (also known as BLLF1 viral late glycoprotein). It is the most abundantly expressed glycoprotein in the viral envelope of Herpesviruses and is the major antigen responsible for stimulating the production of neutralising antibodies in vivo [1]. It is a 907 residues long gp350 polypeptide containing an 18-residue peptide at the C-terminal that is located inside the viral membrane, a membrane-spanning domain and a large N-terminal segment (860 residues) predicted to extend outside the viral membrane. The extreme N-terminal region (1-470) is sufficient to bind receptor CR2 (also known as CD21) and fold into three distinct domains (denoted as A, B and C) which organise into an "L-shape" structure. This is domain B [2].
Herpesvirus envelope glycoprotein gp350 N-terminal C domain
This entry consists of the envelope glycoprotein gp350 from Epstein-Barr virus (also known as BLLF1 viral late glycoprotein). It is the most abundantly expressed glycoprotein in the viral envelope of Herpesviruses and is the major antigen responsible ...
This entry consists of the envelope glycoprotein gp350 from Epstein-Barr virus (also known as BLLF1 viral late glycoprotein). It is the most abundantly expressed glycoprotein in the viral envelope of Herpesviruses and is the major antigen responsible for stimulating the production of neutralising antibodies in vivo [1]. It is a 907 residues long gp350 polypeptide containing an 18-residue peptide at the C-terminal that is located inside the viral membrane, a membrane-spanning domain and a large N-terminal segment (860 residues) predicted to extend outside the viral membrane. The extreme N-terminal region (1-470) is sufficient to bind receptor CR2 (also known as CD21) and fold into three distinct domains (denoted as A, B and C) which organise into an "L-shape" structure. This is domain C [2].
